SJ Medical
SJ Medical
The global cardiovascular landscape is undergoing a profound transformation. As we move away from permanent metallic implants, Bioresorbable Vascular Scaffolds (BVS) have emerged as the "Fourth Revolution" in interventional cardiology. This technology, pioneered by leading China Bioresorbable Vascular Scaffolds Factories, focuses on the philosophy of "leaving nothing behind." Unlike traditional Drug-Eluting Stents (DES), BVS provides temporary mechanical support to the vessel wall before being naturally absorbed by the body, restoring the vessel's vasomotion and physiological function.
At Hangzhou SJ Medical Co., Ltd., we recognize that the future of cardiology lies in Vascular Restoration Therapy (VRT). Established in 2015, our mission has been to bridge the gap between high-end R&D and global clinical accessibility. By integrating advanced polymer science with precision engineering, we offer solutions that mitigate the long-term risks associated with permanent foreign bodies, such as late stent thrombosis and the "caged" vessel effect.
Current scaffolds utilize Poly-L-Lactic Acid (PLLA), a biocompatible polymer that degrades into lactic acid. Our R&D is currently exploring thinner strut profiles and next-gen magnesium alloys to enhance deliverability without compromising radial strength.
The critical challenge is matching the degradation rate with the vessel healing process. Our scaffolds are engineered for a 6-month mechanical stability phase, followed by a 24-month complete resorption window, ensuring optimal clinical outcomes.
Future iterations include radiopaque markers and integration with AI-driven IVUS (Intravascular Ultrasound) for precise placement and real-time monitoring of the resorption process, providing physicians with unprecedented data granularity.
SJ Medical operates a state-of-the-art manufacturing facility built in strict accordance with GMP standards. Our 5,000 square meter facility features a million-class clean workshop with localized hundred-class areas for critical assembly. This "Factory 4.0" approach ensures that every scaffold meets the rigorous demands of global healthcare providers.
Utilizing high-precision laser systems to ensure structural integrity and visibility under fluoroscopy.
Proprietary balloon technology ensures uniform expansion of the scaffold, critical for preventing edge dissections.
Located in the heart of China's medical tech hub, we maintain deep integration with raw material suppliers to guarantee stable pricing and lead times.
As a leading Exporter, SJ Medical understands that regulatory compliance is the bedrock of clinical trust. We have secured CE Certification, ISO 13485, and CFDA approval. Our products are actively used in clinics across Europe (Italy, Spain, France, Netherlands), Asia (India, Indonesia), and the Middle East (Turkey, Egypt).
Our product range integrates interventional access systems, diagnostic catheters, and therapeutic devices. Each product is developed with an emphasis on precision, safety, and clinical performance, aiming to support physicians in achieving optimal procedural outcomes.
Designed for complex lesions, providing the radial strength of metal with the long-term benefits of a "natural" vessel.
Expanding into BTK (Below-The-Knee) and SFA (Superficial Femoral Artery) applications where vessel flexibility is paramount.
We provide 24/7 technical assistance and training for local surgeons to ensure the highest safety standards are met globally.
The rising burden of cardiovascular disease in emerging markets demands cost-effective yet high-quality solutions. SJ Medical addresses this through Macro Industry Solutions that combine high-volume production efficiency with uncompromising quality control. By reducing the "innovation premium" often associated with Western brands, we enable broader access to life-saving BVS technology.
The primary advantage is the restoration of natural vascular physiology. By disappearing after the healing process, BVS allows the vessel to pulsate naturally (vasomotion) and reduces the risk of long-term inflammation or late-stage thrombosis associated with permanent metallic cages.
Every batch undergoes rigorous testing including fatigue resistance, radial force verification, and drug-loading uniformity. We adhere to ISO 13485 standards and hold CE certification, ensuring our products meet the stringent requirements of the European and international markets.
Our PLLA-based scaffolds maintain their radial strength for the first 6-9 months to prevent vessel recoil. Complete resorption usually occurs between 24 and 36 months, leaving behind a healthy, functional artery.
Yes. With our advanced Factory 4.0 infrastructure, we provide comprehensive OEM and ODM solutions, from initial prototype design to regulatory submission support and high-volume manufacturing.
Younger patients often benefit most as they have a longer life expectancy and can avoid the lifelong presence of multiple metallic implants. It is also highly effective for patients requiring subsequent bypass surgery, as the "target zones" remain clear of metal.
